



1 March 2024

Cancellation of Performance Rights

Melbourne, Australia, 1 March 2024: dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**) refers to the issue of 7,400,000 performance rights by the Company on 1 March 2023 as disclosed in the Appendix 3G lodged with ASX on 8 May 2023 (**Performance Rights**). The Company advises that due to an administrative error, 4,000,000 of the Performance Rights were issued to Mr Andrew Ronchi, a Director of the Company, without Shareholder approval in breach of Listing Rule 10.14. The 4,000,000 Performance Rights have been cancelled in order to rectify this breach and an updated Appendix 3G has been lodged with ASX today.

The Company believes the breach was the result of an administrative oversight. A review of the Company's existing policies and procedures has been conducted and the Company is confident of its ability to comply with ASX Listing Rule 10.14 in the future. It will also take appropriate precautions to ensure that breaches of the ASX Listing Rules do not occur in the future.

- ENDS -

This announcement has been approved for release by the Board of dorsaVi Ltd.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com